Back to top

Image: Bigstock

United Therapeutics Corporation

Read MoreHide Full Article

United Therapeutics holds a strong position in the pulmonary arterial hypertension (PAH) market with four approved products targeting this indication. The company’s latest PAH offering, Orenitram, should continue to witness a pick-up in sales on the back of new patient starts, increasing patient referrals, and increasing uptake in community centers. However, PAH sales could be impacted by the warehousing effect with patients waiting to be treated with newer products like Orenitram and Actelion’s Uptravi. Meanwhile, we believe the company needs to use cash suitably to deal with generic competition for flagship product Remodulin that could materialize post Oct 2017 and should work on expanding its portfolio. Tyvaso and Orenitram are also facing patent challenges. Competition in the PAH market is also increasing.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

United Therapeutics Corporation (UTHR) - free report >>

Published in